Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic approaches for Duchenne muscular dystrophy
Thomas C. Roberts, Matthew J. A. Wood, Kay E. Davies
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 11, pp. 917-934
Closed Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
Xiaochun Bian, Liping Zhou, Zhiwei Luo, et al.
ACS Nano (2025)
Closed Access | Times Cited: 2
Breaking genetic shackles: The advance of base editing in genetic disorder treatment
Fang Xu, Caiyan Zheng, Weihui Xu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 10
Human Genetics and Genomics for Drug Target Identification and Prioritization: Open Targets’ Perspective
Ellen M. McDonagh, Gosia Trynka, Mark I. McCarthy, et al.
Annual Review of Biomedical Data Science (2024) Vol. 7, Iss. 1, pp. 59-81
Closed Access | Times Cited: 9
Combined 20-Hydroxyecdysone and Antisense-Mediated Exon Skipping Improve Functional Outcomes in a Mouse Model of Duchenne Muscular Dystrophy
Mathilde Blitek, Cécile Gastaldi, Mathilde Doisy, et al.
Nucleic Acid Therapeutics (2025)
Open Access | Times Cited: 1
G-Quadruplex-Based Splice Switching as a Therapeutic Approach in Duchenne Muscular Dystrophy
Ryo Iwase, Taro Ishiguro, Hiroya Kuwahara, et al.
ACS Chemical Biology (2025)
Open Access | Times Cited: 1
Mutations causing premature termination codons discriminate and generate cellular and clinical variability in HHT
María E Bernabeu-Herrero, Dilipkumar Patel, Adrianna Bielowka, et al.
Blood (2024) Vol. 143, Iss. 22, pp. 2314-2331
Open Access | Times Cited: 8
Tumor Microenvironment‐Responsive Nanocapsule Delivery CRISPR/Cas9 to Reprogram the Immunosuppressive Microenvironment in Hepatoma Carcinoma
Lei He, Zhaozhao Li, Danjie Su, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Open Access | Times Cited: 8
Mitochondria and Reactive Oxygen Species: The Therapeutic Balance of Powers for Duchenne Muscular Dystrophy
Silvia Rosanna Casati, Davide Cervia, Paulina Roux-Biejat, et al.
Cells (2024) Vol. 13, Iss. 7, pp. 574-574
Open Access | Times Cited: 6
RNA Sequencing in Disease Diagnosis
Craig Smail, Stephen B. Montgomery
Annual Review of Genomics and Human Genetics (2024) Vol. 25, Iss. 1, pp. 353-367
Closed Access | Times Cited: 4
Oral administration of plumbagin is beneficial in in vivo models of Duchenne muscular dystrophy through control of redox signaling
Davide Cervia, Silvia Zecchini, Luca Pincigher, et al.
Free Radical Biology and Medicine (2024) Vol. 225, pp. 193-207
Open Access | Times Cited: 4
Safety and Tolerability of Wharton’s Jelly-Derived Mesenchymal Stem Cells for Patients With Duchenne Muscular Dystrophy: A Phase 1 Clinical Study
Jiwon Lee, Sang Eon Park, Mi‐Ra Kim, et al.
Journal of Clinical Neurology (2025) Vol. 21, Iss. 1, pp. 40-40
Open Access
When “loss-of-function” means proteostasis burden: Thinking again about coding DNA variants
Claire L. Shovlin, Micheala A. Aldred
The American Journal of Human Genetics (2025) Vol. 112, Iss. 1, pp. 3-10
Closed Access
Muscular Dystrophies and Therapeutic Potential of Medicinal Plants
Mοhd Saeed, Munazzah Tasleem, Ashanul Haque, et al.
Deleted Journal (2025) Vol. 4, Iss. 1
Open Access
Evaluation of Creatine Monohydrate Supplementation on the Gastrocnemius Muscle of Mice with Muscular Dystrophy: A Preliminary Study
Victor Augusto Ramos Fernandes, Gabriela Pereira dos Santos, Amilton Iatecola, et al.
Pathophysiology (2025) Vol. 32, Iss. 1, pp. 2-2
Open Access
Gene Therapy Strategies for Muscular Dystrophies: Current Insights and Future Directions
Mahintaj Dara, Mehdi Dianatpour, Negar Azarpira, et al.
OBM Genetics (2025) Vol. 09, Iss. 01, pp. 1-35
Open Access
Report on the 6th Ottawa International Conference on Neuromuscular Disease & Biology – September 7–9, 2023, Ottawa, Canada
Jodi Warman‐Chardon, Bernard J. Jasmin, Rashmi Kothary, et al.
Journal of Neuromuscular Diseases (2025) Vol. 12, Iss. 1
Closed Access
Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy
Katarzyna Chwalenia, Matthew J. A. Wood, Thomas C. Roberts
Journal of Muscle Research and Cell Motility (2025)
Open Access
Role of Perinatal Stem Cell Secretome as Potential Therapy for Muscular Dystrophies
Serafina Pacilio, Sara Lombardi, Roberta Costa, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 458-458
Open Access
Gene therapy for genetic diseases: challenges and future directions
Beibei QIE, Jingsheng Tuo, Feilong Chen, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access
Expansion of Splice-Switching Therapy with Antisense Oligonucleotides
Yasuhiro Takeshima
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2270-2270
Open Access
The necessity for skeletal muscle contractile assays to assess treatment efficacy in DMD
Chia-Yi Yuan, Amanda Sweeten, Robert W. Grange
Rare Disease and Orphan Drugs Journal (2025) Vol. 4, Iss. 1
Open Access
Activation of endogenous full-length utrophin by MyoAAV-UA as a therapeutic approach for Duchenne muscular dystrophy
Ruo Wu, Peng Li, Puhao Xiao, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Valproic Acid Improves Antisense-Mediated Exon-Skipping Efficacy in mdx Mice
Micky Phongsavanh, Flavien Bizot, Amel Saoudi, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2583-2583
Open Access
Recent advances in RNA-based therapeutics for neurodevelopmental disorders
Harini P Tirumala, Huda Y. Zoghbi
Current Opinion in Genetics & Development (2025) Vol. 92, pp. 102339-102339
Closed Access
Is dystrophin immunogenicity a barrier to advancing gene therapy for Duchenne muscular dystrophy?
Dariusz C. Górecki, Paweł Kaliński, Joanna Pomeroy
Gene Therapy (2025)
Open Access
Page 1 - Next Page

Scroll to top